Mayzent (siponimod)
The FDA approved Mayzent (siponimod) tablets to treat adults with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.
Mayzent was shown to be effective in a clinical trial of 1651 patients that compared Mayzent to placebo with patients with secondary progressive multiple sclerosis (SPMS). The fraction of patients with confirmed progression of disability was statistically significantly lower in the Mayzent group than in the placebo group, and Mayzent decreased the number of relapses. The sub-group of patients with non-active SPMS did not see statistically significant results.
Read the full FDA Press Release here.
Mavenclad (cladribine)
Mavenclad (cladribine) is FDA approved to treat relapsing forms of MS in adults, to include relapsing-remitting disease and active secondary progressive disease, but not recommended for relapsing-remitting disease or active secondary progressive disease. Mavenclad is recommended for patients with inadequate response to alternative drugs for MS.
Read the full FDA Press Release here.
Read PEPID’s Primary Care Plus Ambulatory Care Multiple Sclerosis Disease Monograph Card here.
[elfsight_social_share_buttons id=”3″]